BUSINESS

1. Contract research of protein crystallization in microgravity

Accelerating Structure-based Drug Development Through Space-based Protein Crystallization

Space LiinTech provides contract-based research services for protein crystallization under microgravity, addressing the limitations imposed by gravity on Earth—such as convection, secondary nucleation, aggregation, and polymorphism. These phenomena often hinder crystal uniformity and size, ultimately impacting structural discernibility in drug development.

By utilizing microgravity conditions in space, we facilitate the formation of larger, more uniform crystals, including those that are difficult to crystallize on Earth. This allows for high-resolution structural analysis—down to hydrogen-bond-level precision—and accelerates the structure-based drug discovery process.

2. Contract production of pharmaceuticals and API using microgravity

Expanding Korea’s API Capabilities Through Space-based Manufacturing

Space LiinTech pioneers pharmaceutical and active pharmaceutical ingredient (API) production under microgravity, contributing to Korea’s expanding API industrial ecosystem.

Leveraging space's physical benefits—such as reduced shear stress and improved molecular diffusion—we develop high-purity biologics and APIs that are difficult to synthesize under Earth’s gravity. Our space-based production modules integrate key features such as automation, real-time environmental monitoring, and advanced process control, laying the foundation for next-generation biomanufacturing in orbit.

3. Research and Development of Cellular Therapeutics

Gravito-Electroporation: A Platform for High-Efficiency Gene Delivery

Space LiinTech is developing a novel gene delivery platform for cell therapies by harnessing gravitational dynamics. Variable gravity provides a stable and uniform environment for electroporation, improving gene transfer efficiency and post-transfection viability.

Our proprietary Gravito-Electroporation technology efficiently delivers genetic material across diverse cell types while minimizing cell damage. This platform has the potential to significantly improve transfection outcomes for next-generation cell and gene therapies.

1. Space Station based Research Platform

Protein Crystallization on the International Space Station

Space LiinTech operates a microgravity-based drug development platform aboard the International Space Station (ISS), focusing on protein crystallization and organoid generation. This platform is designed to support the development of complex therapeutics, including immuno-oncology drugs and treatments for infectious diseases such as COVID-19.

We are working closely with U.S.-based launch providers and global partners, targeting our first launch by mid-2025 and initiating commercial platform services by 2027. The ISS environment enables the growth of high-quality protein crystals that are difficult to form on Earth, accelerating structural analysis and reducing overall drug development time and cost.

2. Satellite-based Platform for Biopharmaceutical Research

Deploying LEO Satellite Modules for Protein Crystallization and Bioproduction

Space LiinTech develops and operates satellite-based modules in low Earth orbit (LEO) for protein crystallization and microgravity-enabled bioproduction. These platforms are engineered to support commercial-scale drug development in space.

We collaborate with a network of domestic and international launch providers and in-orbit service partners to ensure seamless integration, launch, and operation of our LEO biotechnology infrastructure.

3. Ground-Based Drop Tower Transfection Platform

Gravitational Biology Research Using Earth-Based Microgravity Analog Systems

Drop towers induce microgravity conditions (approx. 10⁻³ to 10⁻⁶ G) during brief periods of free fall, allowing essential biomedical experiments to be performed under near-weightless environments. Space LiinTech operates multiple drop tower facilities to support the development and validation of space biopharmaceutical technologies, particularly in the field of gene transfection.

The Jeongseon Drop Tower, developed with the Institute for Basic Science (IBS), utilizes a vertical mine shaft for experiments under controlled microgravity.
A new 900-meter-class drop tower—the world’s longest—is under construction at the Jangseong Mining Complex in Taebaek.
In addition, compact drop towers for indoor use have been developed and are actively used at our Gravity Lab in Giheung.

Our drop tower systems enable scalable, customizable platforms for transfection research and simulation-based validation of microgravity applications on Earth.

Space LiinTech, a pioneering space medicine company in South Korea, is developing a next-generation pharmaceutical ecosystem that extends across Earth and orbit.

Our business model integrates low Earth orbit (LEO) platforms for bio-research and pharmaceutical production, proprietary drop towers for gravity simulation, and launch coordination services.

Through this multi-platform approach—spanning ground-based systems, space stations, and satellites—we provide commercial solutions for:

Structure-based drug discovery using protein crystallization in microgravity
Contract manufacturing of active pharmaceutical ingredients and biologics in space
Cell therapy research powered gene delivery by varying gravity.

By bridging the gap between terrestrial and space-based biotech, Space LiinTech is redefining what’s possible in pharmaceutical innovation.

Platform Infrastructure for Space Biopharmaceutics Innovation

Core Platforms for Space Biopharmaceutical Validation

BEE-PC1
( Protein Crystallization )

BEE-1006

BEE-1012

BEE-FRM / FPM

How We Deliver Space Biopharmaceutics Innovation